基本信息
浏览量:211
职业迁徙
个人简介
Chow has extensive clinical trials experience; a strong background in clinical pharmacology, therapeutics and developmental therapeutics; and excellent Canadian and USA internal medicine and clinical medical oncology skills and training. Her clinical expertise is in head and neck cancers, thyroid cancer and lung cancers with a national and international reputation as a researcher focused on novel therapeutics and early phase clinical trials, immunotherapy and head and neck cancers, thyroid cancers and lung cancers. She has helped develop and bring forth many novel drugs, including the PD-1 immune-checkpoint inhibitors, into regulatory approval as standard-of-care treatments for head and neck cancers and lung cancer. She has been the lead principal investigator of over 40 early phase thoracic and head and neck cancer trials with over 65 publications in high-impact journals, with a clinical research interest focused on developing novel lung and head and neck cancer immune-checkpoint therapies and new combination immunotherapeutics.
研究兴趣
论文共 95 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
openalex(2023)
D. S-W. Tan,M. Thomas,D-W. Kim,S. Szpakowski,P. Urban,R. Mehra,L. Q. M. Chow,S. Sharma,B. J. Solomon,E. Felip,D. R. Camidge,J. Vansteenkiste, L. Petruzzelli, S. Pantano,A. T. Shaw
Khanh T Do,Laura Quan Man Chow,Karen Reckamp,Rachel E Sanborn,Howard Burris,Francisco Robert,D Ross Camidge,Conor E Steuer,John H Strickler,Amy Weise,Jennifer M Specht,Martin Gutierrez, Peter Haughney,Shawna Hengel, Christina Louise Derleth,Timothy A Yap
Revue des maladies respiratoires actualitésno. 1 (2020): 208-209
B. C. Creelan,T. Yeh,S-W. Kim,N. Nogami,D-W. Kim,L. Q. Chow,S. Kanda, R. Taylor,W. Tang, M. Tang,H. K. Angell, M. P. Roudier,M. Marotti,D. L. Gibbons
加载更多
作者统计
#Papers: 95
#Citation: 13067
H-Index: 28
G-Index: 74
Sociability: 7
Diversity: 2
Activity: 12
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn